Sahajanand Medical Technologies

Technologically Advanced Products in High Barrier Segments

The company holds a comprehensive portfolio of advanced cardiovascular implants including DES, Drug-coated balloons, PTCA balloons, TAVI systems, and Occluders, supported by strong clinical evidence and compliant with stringent domestic and international regulatory standards.

Flagship DES – Supraflex Cruz with Superior Deliverability

The company's flagship DES, Supraflex Cruz, is positioned as the 'most deliverable' stent in its class per the F&S Report, with 28,383 clinical trial participants globally and results published in top-tier journals such as The Lancet (impact factor 109) and NEJM (impact factor 84.5).

Proven Research and Development Capabilities

The company operates two R&D centers (India and Thailand) with 156 professionals, holding 119 patents granted globally, 78 patent applications in the pipeline, and R&D expenses of ₹1,041.64 million (8.61% of revenue) in Fiscal 2026.

World-First Innovation in Biodegradable Polymer DES

The company was the first in the world to receive CE certification for a biodegradable polymer-based paclitaxel-eluting stent (Infinnium) in December 2005, and further developed the proprietary LDZ link enhancing deliverability of Supraflex Cruz, per the F&S Report.

Leadership in India and Key International DES Markets

The company holds nearly 25% market share in India's DES sales volume in Fiscal 2026 and is among the top five companies by DES sales volume in Germany, Spain, Poland, and Brazil, and top five in Occluder sales in Thailand, South Korea, and India, as of March 31, 2026.

Deep Global Sales and Marketing Presence

The company marketed products in 77 countries in Fiscal 2026, with international revenue growing at a CAGR of 23.34% from ₹5,878.44 million (Fiscal 2024) to ₹8,942.01 million (Fiscal 2026), operating across 6 direct, 20 hybrid, and 39 distributor-led markets.

Diversified, Integrated, and Efficient Manufacturing Facilities

The company operates three integrated manufacturing facilities in Surat, Hyderabad (India), and Nonthaburi (Thailand), accredited by CE, ANVISA, TGA Australia, Korean GMP, and Health Canada, with ~33% of Hyderabad's available area currently utilized, allowing scalable expansion.

Proven M&A and Strategic Collaborations Playbook

The company has successfully completed four acquisitions in seven years, including Vascular Concepts, Vascular Innovations, Imex (Spain), and Zarek (Brazil), achieving a combined CAGR of 34.32% from Imex and Zarek since Fiscal 2020, and expanding SH revenue to ₹2,030.62 million in Fiscal 2026.

Experienced Leadership Team Backed by Reputed Institutional Investors

The company's senior leadership team of 11 members (KMPs and SMPs) averages 26 years of industry experience and 8 years of tenure, supported by investors including Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund, Plutus Wealth Management LLP, and Ashish Kacholia.

Extensive Regulatory Requirements and Adverse Regulatory Actions

The company is subject to rigorous regulation across multiple jurisdictions, including India's Medical Devices Rules, 2017 and the EU MDR, requiring continuous approvals and certifications. Any adverse regulatory action, product recall, or failure to obtain/renew approvals could restrict product marketing, increase costs, and materially impact business operations and financial performance.

Revenue Concentration in Vascular Intervention Devices and Supraflex Cruz

Vascular Intervention devices contributed 60.40%–68.57% of revenue from operations across recent periods, with the single product Supraflex Cruz alone contributing 37.17%–47.84% of total revenue. Any adverse impact on sales of this vertical or product — due to competition, regulatory setbacks, pricing controls, or trademark disputes — would materially affect the company's revenues and profitability.

Supplier Concentration and Raw Material Dependency

The company's top 10 suppliers accounted for 58.88%–64.37% of total purchases, with imports comprising approximately 73%–84% of total purchases from countries including China, Netherlands, and Germany. The absence of long-term supply contracts and reliance on single suppliers for critical materials such as cobalt chromium tubes and sirolimus drug exposes the company to significant supply disruption and pricing volatility risks.

Manufacturing Facility Risks and Quality Control Issues

The company operates three manufacturing facilities in India and Thailand, which are exposed to risks including equipment breakdowns, quality control failures, labor disruptions, and regulatory non-compliance. Any manufacturing disruption, product defect, or quality failure could result in product recalls, reputational damage, loss of regulatory certifications, and adverse financial impacts.

Foreign Currency Exchange Rate Fluctuations

Revenues from customers outside India represented 68.71%–76.16% of total revenue from operations, while imports in foreign currencies amounted to ₹1,954.09–₹2,410.02 million annually. The company is exposed to significant currency translation and transaction risks across multiple currencies, and its hedging strategy may not fully protect against foreign exchange volatility, potentially impacting margins and financial results.

Regulatory Pricing Controls and NPPA Price Ceilings

The company's drug-eluting stents, including Supraflex Cruz, are subject to price ceilings set by India's National Pharmaceutical Pricing Authority (NPPA) under the NLEM framework. Any extension of price controls to additional products, inability to pass on raw material cost increases, or non-compliance with pricing regulations (which could result in criminal prosecution under the Essential Commodities Act) could materially affect revenues and profitability.

Intense Competition and Rapid Technological Change

The medical device market is intensely competitive, with multinational and domestic companies possessing significantly greater resources and broader product portfolios. Failure to continuously innovate, reduce production costs, or adapt to new technologies and therapies could erode the company's market share, competitive position, and financial performance.

High Working Capital Requirements and Liquidity Risk

The company's average working capital stood at ₹2,914.40 million in Fiscal 2026, with working capital loans outstanding of ₹2,409.91 million as of June 30, 2026. Inability to maintain adequate working capital through internal accruals or external financing could disrupt operations, limit growth, and adversely affect financial condition and results of operations.

Historical Losses in Subsidiaries and Consolidated Financial Risk

Several subsidiaries, including Vascular Innovations Co Ltd (loss of ₹120.07 million in Fiscal 2026) and SMT Switzerland AG (loss of ₹56.31 million in Fiscal 2026), have incurred losses, and the company on a standalone basis reported a loss of ₹79.18 million in Fiscal 2025. Continued losses in subsidiaries may require financial support from the parent, restrict research activities, and adversely affect consolidated financial performance.

International Operations Risks Including Sanctions Exposure

The company sells products across 65–77 countries, with revenues from sanctioned jurisdictions including Iran (1.41%–4.66% of revenue) and Russia (2.97%–3.92% of revenue) in recent fiscal years. Evolving international sanctions regimes, geopolitical tensions, trade tariffs, and varying regulatory requirements across markets could restrict market access, disrupt distributor relationships, and materially impact international revenues and operations.